Chronic bronchial sepsis and progressive lung damage
The clinical pattern of bronchiectasis has altered in the past 50 years. Reports of patients with profuse foul sputum and a high mortality from pneumonia and cor pulmonale are now less common,'4 while predisposing factors such as whooping cough, pneumonia, and tuberculosis have been reduced by immunisation and effective treatment with antibiotics. Though pathologically bronchiectasis is defined as a permanent abnormal dilatation of one or more large bronchi, clinicians5still associate the disease with regular production of purulent sputum.
With the reduction in "old fashioned bronchiectasis" other causes for the development ofchronic purulent sputum production have been reported. Cystic fibrosis in the adolescent is characterised by severe bronchiectasis with airflow obstruction, pneumothoraces, haemoptysis, and reduced life expectancy.56 Bronchopulmonary aspergillosis, primary ciliary dyskinesias, and specific immunological deficiencies may all lead to bronchiectasis, but they will not be considered further here.
A more recently recognised form of chronic bronchial sepsis has been described in patients seen by Cole at the Brompton Hospital Host Defence Unit.'2 These patients are non-smokers and appear to have no obvious cause for the development of bronchiectasis. Many of Cole's patients had raised serum concentrations of immunoglobulins, frequently associated with an inhibitory factor for lymphocyte function, and they also had a higher than expected incidence of positive test results for autoantibodies.'2 Most also had progressive lung damage with scarring, shrinking of the lung, and airflow obstruction-despite regular postural drainage and bronchodilators. Cole postulates a "vicious circle" hypothesis, with an initial event damaging the lung and secondary colonisation by an apparently avirulent organism (such as Haemophilus influenzae) leading to progressive heavy bacterial colonisation and increasing lung damage. 12 This disease pattern implies a failure of the defence mechanism of the lung to eliminate foreign material from the respiratory tract. Normally this is achieved by mucociliary clearance, local antibody responses, and alveolar macrophages; if these defences are breached, however, inflammatory responses may develop with the release, predominantly from neutrophils, of proteolytic enzymes that may damage the lung. Patients with an inherited deficiency of ct antitrypsin have such proteolytic enzymes in their lungs with an imbalance with their respective inhibitors, and this is associated with the development of basal pulmonary emphysema.'3 Moreover, papain, a potent proteolytic enzyme, will produce emphysematous lesions in animals.'4 Stockley's excellent review of lung proteolytic enzymes and their inhibitors noted that sputum elastase'5 (a commonly found proteolytic enzyme in purulent sputum'6'9) may be incriminated in damaging the bronchial epithelium and reducing ciliary function. 20 An imbalance in proteolytic activity is, then, a possible factor in the pathogenesis of bronchiectasis, especially as abnormalities of bronchial epithelium and reducing mucociliary clearance are features of chronic bronchial sepsis. 2' 22 But does it lead to progressive lung damage? Longitudinal studies of respiratory function in bronchiectasis are few. In 1966 Cherniak and Carton concluded that in patients with bronchiectasis "the rate of deterioration of pulmonary function with time is slight whether or not antibiotics are taken daily."23 More recent studies have again suggested only moderate impairment of respiratory function, but in a survey from Edinburgh 22 of 116 patients had died, over a third of them from cor pulmonale.24 25 Though the patients who died had more severe airflow obstruction initially, the rate of decline in forced expired volume in one second in 80% of the survivors was no greater than expected. 26 There may, however, be a subset of patients with bronchiectasis who develop progressive lung damage who have high elastase activity in the sputum and a high sputum to serum albumin ratio, suggesting an active inflammatory reaction within the lung.2728 Stockley and coworkers took a group of patients with stable bronchiectasis with no definable cause but with high sputum elastase activities and treated them with broad spectrum antibiotics (most receiving amoxycillin 250 mg three times a day).29 Treatment was associated with clearing of the sputum of elastase and a dramatic fall in the sputum to serum albumin ratio, suggesting a reduction in active inflammatory reaction within the lung. On stopping treatment with antibiotics the sputum again became purulent, with the return of high activities of elastase. The most common infecting organism was H influenzae, supporting Cole's concept that such organisms may colonise the airway of patients with apparently stable bronchiectasis.12 These workers used a selective culture medium specifically designed to prevent the overgrowth ofPseudomonas aeruginosa swamping other organisms. 2830 Stockley's group noted that, despite the excellent penetration of amoxycillin into the sputum and absence oflactamase activity, four of their 15 patients whose sputum grew H influenzae failed to respond to conventional doses of antibiotics.3' Such patients may respond to higher doses of amoxycillin (3 g twice daily for 10 days) with dramatic improvement both clinically and spirometrically32 and with improvement of mucociliary clearance measured in vitro. 33 In 1957 the Medical Research Council showed that continuous low dose treatment with tetracycline reduced symptoms and sputum volume and also improved the work record of patients with bronchiectasis.4 Any possible effect on improved prognosis was not assessed. Stockley and Cole's reports suggest that the reduction in microbial load using antibiotics, with concomitant reduction in sputum proteolytic activity, should prevent lung damage.1229
Can we identify patients with chronic bronchial sepsis of no obvious cause who are likely to develop lung damage by any means other than measuring the elastase activity in the sputum or by observing irreversible reduction in respiratory function? The question is important, for patients with chronic bronchial sepsis are at risk of systemic amyloidosis, as are patients with pulmonary tuberculosis.35 De Beer et al have reported measurements of C reactive protein and serum amyloid A protein concentrations (associated with the development of secondary amyloidosis) in patients with tuberculosis.3637 Their patients with pulmonary destruction associated with postprimary tuberculosis had very high serum concentrations of amyloid A protein and C reactive protein, and these were maintained over a period of months despite apparent cure of the tuberculosis. By contrast, the acute phase proteins showed only a trivial rise in patients with a primary tuberculous complex; and, although they were raised in patients with postprimary tuberculosis with no lung destruction, their concentrations rapidly returned to normal. The authors attributed the maintained concentrations of acute phase proteins in patients with lung damage to secondary bacterial infection.37 De Beer's patients may possibly have been suffering from progressive lung destruction secondary to a sustained high microbial load with concomitant high elastase activities in the sputum.
Certain therapeutic and investigative measures are essential in treating bronchial sepsis. These include stopping smoking, physiotherapy with postural drainage and forced expiration techniques,38 aggressive treatment with antibiotics for acute exacerbations, and the use of bronchodilators-in some instances with short courses of oral corticosteroids where there is also airflow obstruction.39 Specific causes for chronic bronchial sepsis should be treated, and inhalation of a foreign body should not be forgotten.
The value of long term treatment with antibiotics in patients with chronic bronchial sepsis without a specific cause is difficult to assess. A large microbial load may lead to progressive lung damage. Unfortunately, by no means all clinicians have access to measurements of sputum elastase activity, sputum to serum albumin ratios, and the more refined respiratory function tests. May it be too simple to suggest that patients at risk of progressive lung damage may be identified by the combination of a certain volume of purulent sputum produced each day, simple longitudinal respiratory function testing, and an index of systemic inflammatory response such as the persistence of C reactive proteins? Physicians responsible for such patients would also like to know what antibiotic treatment should be given, by which route, and for how long; they look forward to the answers to these questions.
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